Transtat 500 Special Precautions

In case of haematuria of renal origin (especially in haemophilia), there is a risk of mechanical anuria due to formation of a ureteral clot.
In the long-term treatment of patients with hereditary angioneurotic oedema, regular eye examinations (e.g. visual acuity, slit lamp, intraocular pressure, and visual fields) and liver function tests should be performed.
Patients with irregular menstrual bleeding should not use Tranexamic Acid (Transtat) Film-coated tablets until the cause of irregular bleeding has been established. If menstrual bleeding is not adequately reduced by Tranexamic Acid (Transtat) Film-coated tablets, an alternative treatment should be considered.
Tranexamic acid should be administered with care in patients receiving oral contraceptives because of the increased risk of thrombosis.
Patients with a previous thromboembolic event and a family history of thromboembolic disease (patients with thrombophilia) should use Tranexamic Acid (Transtat) Film-coated tablets only if there is a strong medical indication and under strict medical supervision.
The blood levels are increased in patients with renal insufficiency. Therefore a dose reduction is recommended.
The use of tranexamic acid in cases of increased fibrinolysis due to disseminated intravascular coagulation is not recommended.
Patients who experience visual disturbance should be withdrawn from treatment.
Clinical experience with tranexamic acid in menorrhagic children under 15 years of age is not available.
Cases of convulsions have been reported in association with tranexamic acid treatment. In cardiac surgery, most of these cases were reported following intravenous (i.v.) injection of tranexamic acid in high doses.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Effects on ability to drive and use machines: Tranexamic Acid (Transtat) Film-coated tablets has no or negligible influence on the ability to drive and use machines.